Biotechnology

Nasus Pharma's NS002 nasal spray reached critical therapeutic levels in half the time of EpiPen, heralding a potential new era for anaphylaxis treatment.

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

New data on an oral Parkinson's drug and major strides in rare disease research signal Lundbeck's deep commitment to tackling complex neurological disorders.

Swiss lab-tech firm Tecan posts a major loss after strategic write-downs but launches an ambitious 'Rewired' plan to chase a CHF 1B sales target.

Despite a revenue dip, Kelyniam Global slashed its net loss, secured FDA clearance for a breakthrough implant, and rejected a buyout, charting its own course.

OTC-listed ProText Mobility unveils an audacious plan to tokenize biotech assets, partner with major banks, and uplist to a major exchange. Can it deliver?

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

As it advances its brain cancer therapies, NeOnc Technologies hires a public company finance expert to steer its next growth phase and ensure fiscal rigor.

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.

A new iPSC-derived cell therapy from Unixell Biotech has gained FDA approval for clinical trials, offering a regenerative approach for millions with epilepsy.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

After a strategic pivot and R&D setbacks, Korro Bio secures an $85M lifeline to advance its novel RNA-editing drug for rare metabolic diseases.

Data shows Beren Therapeutics' drug slows progression and boosts survival for infantile-onset NPC, a rare disorder with no approved US treatments.

The 2nd annual Chicago River Swim celebrates the river's historic cleanup, raises funds for ALS research, and promotes youth water safety in a new civic event.

One year post-approval, Neurotech's novel gene therapy implant is transforming patient lives and rewriting the playbook for biotech commercialization.

Global CRO Emerald Clinical Trials has won a major award for its patient-first strategies in the fast-growing, complex Asia-Pacific clinical trial market.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

The specialty infusion provider is the first to earn a rigorous new distinction, signaling a major leap forward in patient safety and quality of care.

The precision oncology firm reports a dramatic cut in net loss and a strategic pivot paying off, bolstered by a new U.S. patent for its cancer tech.

A plant-based gel that stops severe bleeding in seconds is being showcased to top trauma experts, signaling a major shift in emergency medicine.